GRP and prostate carcinoma: Vashchenko and Abrahamsson (17) reported several new useful treatment agents for NE differentiation in prostate cancer, including somatostatin analogs, serotonin antagonists, bombesin antagonists and inflammatory cytokines, such as interleukin-6.